HIV / AIDS in the News

Clinical trial suggests knowing HIV 'viral load' doesn't improve number of patients seeking needed care - European AIDS Treatment Group

 

Gilead’s HIV treatment meets primary trial endpoint - Pharmafile

 

A key to long-term HIV control - National Institutes of Health (NIH) | (.gov)

 

Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial - Reuters

 

Gilead’s experimental HIV treatment meets main goal in late-stage trial - WKZO

 

The Tri-Pharma Tournament: Gilead, ViiV, and MSD Battle for the HIV Drug Cup - geneonline.com

 

Canada's reduced Global Fund pledge threatens health at home and abroad - News-Medical

 

Researchers See Dramatic Drop in HIV-Infected Immune Cells in Patient After Cancer Treatment Received | Newswise - Newswise

 

Higher education increased HIV risk in Africa then became protective - European AIDS Treatment Group

 

Vitamin D and calcium supplements help improve bone density of adolescents with HIV - European AIDS Treatment Group

 

HIV Infections Surge Among Older Adults in China, With Zhejiang Accounting for 40% - Vision Times

 

Population-level data reveal widespread HIV drug resistance in sub-Saharan Africa - European AIDS Treatment Group

 

Researchers see dramatic drop in HIV-infected immune cells in patient after cancer treatment received - European AIDS Treatment Group

 

Gilead’s experimental HIV treatment meets main goal in late-stage trial - WTVB

 

Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial - European AIDS Treatment Group

 

Choose U ambassadors share lived experiences with HIV, personal reflections and insights - Dallas Voice

 

Center for Biostatistics in AIDS Research (CBAR): 2025 Highlights - Harvard T.H. Chan School of Public Health

 

Dramatic drop in HIV-infected immune cells occurs in patient who received cancer treatment - Medical Xpress

 

A testing paradox: Rising sexually transmitted infections cases may mask actual decline in infections - Medical Xpress

 

Gilead posts second Phase 3 win for new HIV-fighting drug regimen - Endpoints News

 

Achieving lasting remission for HIV - Caledonian Record

 

Achieving lasting remission for HIV - The Conway Daily Sun

 

Gilead’s HIV ART combo deemed non-inferior in second Phase III trial - Clinical Trials Arena

 

Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study - Contagion Live

 

Gilead Sciences: Strategic Expansion in HIV Treatment Bolsters Buy Rating - TipRanks

 

Gilead Sciences Reports Positive Phase 3 ARTISTRY-2 HIV Trial Results - Nasdaq

 

How quitting nicotine can benefit people living with HIV - Truth Initiative

 

Panama warns om geople diagnosed with HIV/AIDS - plenglish.com

 

Gilead Yeztugo HIV combo pill meets goal in second phase 3 trial - Seeking Alpha

 

Ryan White never got to go to IU. A new sculpture ensures he will - The Herald-Times